About three-quarters of 39 commercially available sweeteners changed how at least one species of gut bacteria grew when University of Cambridge researchers tested them in the laboratory. The work, from the university’s MRC Toxicology Unit, exposed 25 gut bacterial species to sweeteners both artificial and natural, and it also found that common medicines and food compounds could amplify or blunt those effects. Every result comes from cultures in dishes and simplified microbial communities, not from people.
AI, explained every day: The Deep View is the go-to daily newsletter for 600,000+ founders, knowledge workers and professionals who want to stay up to date with artificial intelligence.
We may earn a commission if you sign up.
Sonja Blasche of the MRC Toxicology Unit, the paper’s lead author, said sweeteners are often marketed as metabolically neutral and that the study challenges that idea. Senior author Kiran Patil said sweeteners “don’t just pass through the body passively” and that medications can amplify or alter their effects. Both statements describe what the cultures showed, and the authors are explicit that the experiments were conducted in the laboratory rather than in humans.
Thirty-nine sweeteners against 25 gut species
The study appeared on June 25, 2026 in Molecular Systems Biology as “Common xenobiotics modulate gut microbial responses to low-calorie sweeteners in vitro.” The team grew 25 gut bacterial species, a set that the University of Cambridge release says includes beneficial, neutral and potentially harmful organisms, and exposed each one to 39 commercial sweeteners. The paper reports that three-quarters of the tested sweeteners individually affected the growth of at least one strain. Neither the paper nor the release gives an exact count, so this article keeps to the three-quarters figure the authors state rather than converting it into a number of products.
Confirming each hit was a separate step. The paper counts 30 confirmed interactions between five bacterial strains and 26 sweeteners, so the three-quarters share describes a broad screen while the verified set is smaller. According to the Cambridge release, some sweeteners slowed or stopped the growth of bacteria linked to a healthy gut. The release adds that most earlier evidence on sweeteners came from animal studies or population surveys, which is the gap a controlled culture screen is meant to fill.
The story also has a timeline worth keeping straight. The university published its account on July 16, 2026 and updated it on July 20 to clarify that isosteviol comes from stevia; ScienceDaily carried it on July 17, and posted the research again on Oct. 17. The October date is a repost, not a new result.
Isosteviol and duloxetine, the strongest pairing
The researchers then tested sweeteners alongside caffeine, vanillin, advantame and common drugs, and found more than 100 interactions in which a sweetener’s effect shifted. According to the release, effects were intensified in 34 cases and weakened in 68. The paper’s own tally is 102 interactions, 68 of them antagonistic and 34 synergistic. In plain terms, adding a second substance more often dampened a sweetener’s effect on bacterial growth than increased it, though the direction varied from pair to pair.
The strongest result paired isosteviol, a sweetener derived from stevia, with duloxetine, an antidepressant. Together they strongly suppressed Roseburia intestinalis and Parabacteroides merdae, two species involved in digestive health. In a synthetic community of all 25 species the same combination reduced microbial diversity and changed which species thrived and which declined. The release points out that more than 4.2 million patients in the United States were prescribed duloxetine in 2023.
The paper traces the interaction to altered small-molecule transport, drawing on proteomic, metabolomic and genetic data. It also reports that fluid taken from the disrupted community increased toxicity to HeLa cells and changed the secretion of the inflammatory signals IL-6 and IL-8 by Caco-2 cells, both human cell lines. The Cambridge release describes this as an effect on cells involved in inflammation and immune responses. Those are cell-line results from liquid that bacteria had been growing in, so they say nothing yet about a gut inside a living person.
What a culture-dish result can and cannot say
The release says the experiments did not involve people and that more research is needed before concluding there are direct health effects. It is unclear whether the changes would appear on ordinary diets, at everyday doses, or in a real gut with its far larger microbial community. Holly Neill, a nutritionist at the company Bio&Me, cautioned in a Sept. 23 FoodNavigator article that cell-based work has many limitations and should not be assumed to apply to humans, given how much microbiomes differ between individuals.
That outside piece also lists the human evidence that does exist. A 2022 Johns Hopkins study of 120 adults found that two weeks of saccharin, sucralose, aspartame or stevia altered gut and oral microbiomes, and that saccharin and sucralose impaired blood sugar responses. A 2025 literature review cited there found that results across studies conflict. FoodNavigator also notes that the World Health Organization’s 2023 guideline recommends against using sweeteners to control weight or reduce the risk of non-communicable disease, with an exception for people who already have diabetes.
The Cambridge team’s own recommendation is narrower than any dietary advice: sweeteners should be studied together with the drugs and food compounds that people actually consume. Funding came from the European Union’s Horizon 2020 programme and the UK Medical Research Council. The unresolved question is whether a suppressed Roseburia intestinalis in a flask has any counterpart in people who take duloxetine and use stevia-based sweeteners at the same time, and the experiments reported here cannot answer it.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
AI, explained every day: Get The Deep View →
We may earn a commission if you sign up.
More from Morning Overview
